Revenue has effectively evaporated to zero in recent quarters, while operating losses remain stubbornly elevated, frequently exceeding $3 million per quarter.
| Sales/Revenue | 0 | 42K | 181K | 0 | 134K | 571K | 365K | 236K | 500K | 0 | 0 | 0 |
| Revenue Growth % | -100% | -76.8% | - | -100% | -76.53% | 56.44% | 54.66% | -52.8% | - | - | - | - |
| Cost of Goods Sold | 15K | 42K | 172K | 56K | 165K | 373K | 300K | 448K | 0 | 43K | 35K | 28K |
| COGS % of Revenue | - | 100% | 95.03% | - | 123.13% | 65.32% | 82.19% | 189.83% | - | - | - | - |
| Gross Profit | -15K | 0 | 9K | -56K | -31K | 198K | 65K | -212K | 500K | -43K | -35K | -28K |
| Gross Margin % | - | - | 4.97% | - | -23.13% | 34.68% | 17.81% | -89.83% | 100% | - | - | - |
| Gross Profit Growth % | - | -100% | 116.07% | -80.65% | -115.66% | 204.62% | 130.66% | -142.4% | 1262.79% | -22.86% | -25% | - |
| Operating Expenses | 12.49M | 11.53M | 9.59M | 8.88M | 13.04M | 12.41M | 11.23M | 11.24M | 11.36M | 11.34M | 5.37M | 3.7M |
| OpEx % of Revenue | - | 27450% | 5300.55% | - | 9729.1% | 2174.26% | 3077.53% | 4763.56% | 2272.2% | - | - | - |
| Selling, General & Admin | 5.37M | 5.53M | 5.09M | 4.43M | 7.25M | 5.69M | 4.85M | 4.28M | 2.84M | 8.57M | 2.72M | 1.59M |
| SG&A % of Revenue | - | 13154.76% | 2814.92% | - | 5412.69% | 996.5% | 1329.04% | 1813.98% | 568.6% | - | - | - |
| Research & Development | 7.12M | 6M | 4.5M | 4.45M | 5.78M | 6.77M | 6.38M | 6.96M | 8.52M | 2.77M | 2.65M | 2.12M |
| R&D % of Revenue | - | 14295.24% | 2485.64% | - | 4316.42% | 1185.81% | 1748.49% | 2949.58% | 1703.6% | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | -46K | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -12.51M | -11.53M | -9.59M | -8.94M | -13.07M | -12.22M | -11.17M | -11.45M | -10.86M | 11.34M | -5.37M | -3.7M |
| Operating Margin % | - | -27450% | -5295.58% | - | -9752.24% | -2139.58% | -3059.73% | -4853.39% | -2172.2% | - | - | - |
| Operating Income Growth % | - | -20.28% | -7.21% | 31.59% | -6.97% | -9.39% | 2.5% | -5.46% | -195.75% | 311.35% | -45.01% | - |
| EBITDA | -12.48M | -11.5M | -9.54M | -8.88M | -13M | -12.16M | -11.11M | -11.22M | -10.81M | 11.39M | -5.33M | -3.67M |
| EBITDA Margin % | - | -27378.57% | -5270.17% | - | -9704.48% | -2130.3% | -3042.47% | -4752.54% | -2161.4% | - | - | - |
| EBITDA Growth % | -24.2% | -20.55% | -7.37% | 31.68% | -6.91% | -9.54% | 0.99% | -3.78% | -194.91% | 313.54% | -45.17% | - |
| D&A (Non-Cash Add-back) | 29K | 30K | 46K | 56K | 64K | 53K | 63K | 238K | 54K | 43K | 35K | 28K |
| EBIT | -12.45M | -11.53M | -9.59M | -8.86M | -12.93M | -12.22M | -11.17M | -10.71M | -10.86M | -11.09M | -1.06M | -4.15M |
| Net Interest Income | 12K | 0 | 58K | 31K | 83K | -29K | -28K | -84K | 34K | 0 | 0 | 0 |
| Interest Income | 12K | 0 | 58K | 31K | 83K | 0 | 0 | 0 | 34K | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 29K | 28K | 84K | 0 | 0 | 0 | 0 |
| Other Income/Expense | 128K | 90K | 58K | 80K | 134K | -29K | -28K | 659K | 557K | 146K | 4.17M | -581K |
| Pretax Income | -12.38M | -11.44M | -9.53M | -8.86M | -12.93M | -12.25M | -11.2M | -10.79M | -10.3M | -11.2M | -1.2M | -4.28M |
| Pretax Margin % | - | -27235.71% | -5263.54% | - | -9652.24% | -2144.66% | -3067.4% | -4574.15% | -2060.8% | - | - | - |
| Income Tax | 0 | 0 | 14K | 29K | 137K | -59K | 20K | 0 | 0 | -146K | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | -0.15% | -0.33% | -1.06% | 0.48% | -0.18% | 0% | 0% | 1.3% | 0% | 0% |
| Net Income | -12.38M | -11.44M | -9.54M | -8.89M | -13.07M | -12.19M | -11.22M | -10.79M | -10.3M | -11.2M | -1.2M | -4.28M |
| Net Margin % | - | -27235.71% | -5271.27% | - | -9754.48% | -2134.33% | -3072.88% | -4574.15% | -2060.8% | - | - | - |
| Net Income Growth % | -22.65% | -19.89% | -7.33% | 31.99% | -7.25% | -8.66% | -3.9% | -4.77% | 7.98% | -833.86% | 72% | - |
| Net Income (Continuing) | -12.38M | -11.44M | -9.54M | -8.89M | -13.07M | -12.19M | -11.22M | -10.79M | -10.3M | -11.2M | -1.2M | -4.28M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.26 | -0.25 | -0.25 | -0.31 | -0.45 | -0.47 | -0.54 | -0.90 | -1.29 | -0.94 | -0.10 | -0.36 |
| EPS Growth % | -164.19% | 0% | 19.35% | 31.11% | 4.26% | 12.96% | 40% | 30.23% | -37.23% | -840% | 72.22% | - |
| EPS (Basic) | - | -0.25 | -0.25 | -0.31 | -0.45 | -0.47 | -0.54 | -0.90 | -0.91 | -1.31 | -0.14 | -0.36 |
| Diluted Shares Outstanding | 47.76M | 46.19M | 37.65M | 29.01M | 28.81M | 26.13M | 18.42M | 12.15M | 11.51M | 11.9M | 11.9M | 11.9M |
| Basic Shares Outstanding | 47.76M | 46.19M | 37.65M | 29.01M | 28.81M | 26.13M | 18.42M | 12.15M | 11.37M | 8.57M | 8.57M | 11.9M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |
Clinical milestone funding dependency
As reported in financial statements, Entera Bio's revenue has effectively evaporated, with the most recent quarterly figures showing zero revenue compared to sporadic historical milestones, underscoring the company's total reliance on non-recurring research collaborations rather than any sustainable commercial product sales or recurring operational income streams.
The absence of consistent revenue suggests that the company remains in a pre-commercial phase where financial performance is entirely decoupled from market demand. Investors should monitor the lack of top-line growth as a signal that the platform has yet to achieve the commercial validation required to transition away from project-based funding.
Based on the company's reported figures, research and development expenses consistently consume the majority of operating capital, with quarterly R&D spend reaching as high as $2.2 million, which highlights a rigid cost structure that leaves little room for operational efficiency improvements in the current clinical-stage environment.
The high concentration of spending in R&D indicates that the firm is prioritizing clinical trial progression over administrative leaness. This cost profile appears to be a structural necessity for a biotech firm, yet it creates a persistent drag on the income statement that will likely continue until a successful clinical outcome is achieved.
According to recent SEC filings, Entera Bio's operating losses have remained stubbornly elevated, with quarterly operating losses frequently exceeding $3 million, indicating that the company has yet to demonstrate any meaningful operating leverage as expenses continue to scale independently of the negligible and inconsistent revenue generated.
The lack of operating leverage suggests that the company's current business model is not yet optimized for cost-effective scaling. Without a commercial product to absorb fixed overhead, the firm remains trapped in a cycle where every dollar of R&D investment directly deepens the net loss, warranting further investigation into the timeline for potential cost rationalization.
As indicated by the provided data, the company's cash burn rate relative to its limited cash reserves suggests a precarious financial position, where the absence of a clear path to commercial revenue may force management to seek dilutive financing to sustain ongoing clinical development efforts.
Short-sellers would likely focus on the widening gap between cash reserves and the high quarterly burn rate, which may indicate an impending need for capital. This dynamic suggests that the company's long-term viability is highly sensitive to external funding conditions, which could lead to significant equity dilution for existing shareholders.
Quick answers to the most common questions about buying ENTX stock.
For fiscal year 2025, Entera Bio Ltd. (ENTX) reported total revenue of $0.0M.
Entera Bio Ltd. (ENTX) reported a net loss of $11.4M for the fiscal year ending 2025.
Entera Bio Ltd. (ENTX) reported an operating income of $-11.5M, resulting in an operating profit margin of -27450.0%. This margin reflects the operational efficiency of the business before interest and taxes.